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Results of second-time angioplasty and stenting
for femoropopliteal occlusive disease and factors
affecting outcomes
William P. Robinson III, MD,a Louis L. Nguyen, MD, MPH, MBA,b Richard Bafford, MD, MSPH,b
and Michael Belkin, MD,b Worcester and Boston, Mass
Objective: Repeat percutaneous endoluminal interventions for femoropopliteal occlusive disease are common, but the
outcomes are poorly understood. We sought to determine the results of second-time femoropopliteal percutaneous
transluminal angioplasty/stenting (SPTAS) and identify factors associated with success or failure of a continued
endoluminal revascularization strategy.
Methods: A retrospective review of patients undergoing multiple percutaneous endoluminal lower extremity interventions
at a single institution from 2002 and 2009 identified 70 SPTAS in 70 limbs. Patient comorbidities, anatomic severity of
disease, and procedural characteristics were analyzed with respect to outcomes with descriptive statistics, Kaplan-Meier
curves, and Cox proportional hazards modeling. Patency rates were determined from the time of SPTAS.
Results: Patients included 37 men (63%) and 22 women (27%) at a mean age of 70  10 years. Indications for SPTAS
included claudication in 54 limbs (77%) and critical limb ischemia (CLI) in 16 (23%). Median time from the initial
endoluminal intervention to SPTAS was 330 days. Lesion TransAtlantic InterSociety Consensus II (TASCII) classifica-
tion was A in 18 (25.7%), B in 18 (25.7%), C in 25 (35.7%), and D in 9 (12.9%). Technical success was achieved in 68
(97%) with low rates of intraprocedural (10%) and postprocedural (4%) complications as well as initial clinical
improvement in 61 (87%) patients. Over a median follow-up of 22.9 months following SPTAS, 2-year primary patency,
secondary patency, limb salvage (in patients with CLI), and survival were 33%  7%, 63%  7%, 87%  9%, and 88% 
5%, respectively. Cox proportional hazard modeling showed that SPTAS within 180 days of the initial endovascular
intervention was the only significant predictor of failure of primary patency (hazard ratio, 2.65; 95% confidence interval,
1.4-5.2) and secondary patency (hazard ratio, 3.1; 95% confidence interval, 1.4-7.1) of SPTAS.
Conclusions: Second-time femoropopliteal angioplasty/stenting has excellent technical success but limited midterm
primary and secondary patency. Early failure of the initial endovascular intervention strongly predicts poor outcome
following SPTAS and in this cohort was more significant than comorbidities, anatomic factors, or procedural character-
istics. These data suggest that after early endovascular failure, alternatives to a continued endoluminal strategy should be
adopted. (J Vasc Surg 2011;53:651-7.)
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pThe utilization of endovascular interventions for lower
extremity ischemia has increased by more than 300% in the
past decade.1 Percutaneous transluminal angioplasty with
or without stenting has emerged in many centers as a
first-line therapy for infrainguinal arterial occlusive disease,
with the majority of interventions performed in the femo-
ropopliteal segment. The minimally invasive nature of en-
doluminal intervention makes it extremely attractive initial
therapy to patients and physicians alike.
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doi:10.1016/j.jvs.2010.09.020However, the durability of endovascular therapy is of
ajor concern, with primary patency of angioplasty with or
ithout stenting reported to be 47% to 75% at 1 year, 42%
o 60% at 3 years, and 26% to 52% at 5 years.2-7 Accord-
ngly, a significant portion of endoluminal revasculariza-
ions may require secondary interventions due to failure of
he initial procedure. However, the outcomes of second-
ime percutaneous transluminal angioplasty with or with-
ut stenting (SPTAS) are not known. Furthermore, the
atient, anatomic, and procedural characteristics associated
ith the outcome of SPTAS have not been described. The
iterature currently offers only indirect information on the
uccess of secondary endovascular procedures. Primary as-
isted and secondary patency of primary endovascular inter-
entions is reported to be 55% to 75% at 18 months to 3
ears.4,5,7 There may be an implicit belief that the second
ntervention, if required, will be at least as successful as the
nitial intervention, and this assumption seems to be driving
he promulgation of endovascular therapy for infrainguinal
cclusive disease. In addition, methodologic problems in
uch of the current endovascular literature make it difficult
o evaluate the effectiveness of repeat interventions. Re-
orts often focus on the need for “target lesion revascular-
zation”, which is both prone to significant subjectivity and
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March 2011652 Robinson et alfails to address the more clinically relevant issue of the need
to revascularize the same arterial segment due to evidence
of insufficient or jeopardized flow. Variations in the report-
ing of patency criteria, patient follow-up, and surveillance
further hinder the assessment of the outcomes of secondary
endovascular interventions.
Vascular surgeons and other interventionalists will in-
creasingly face decisions regarding the relative utility of
continued endovascular intervention vs alternative strate-
gies such as medical therapy and surgical bypass. The goal
of this study was to determine the results of second-time
femoropopliteal percutaneous transluminal angioplasty/
stenting (SPTAS) and identify the factors associated with
outcome.
METHODS
Patients and procedures. All patients undergoing
lower extremity diagnostic or interventional procedures at
the Brigham and Women’s Hospital are prospectively en-
tered into our clinical database. Our database was searched
for patients who underwent lower extremity angiography
and/or intervention between January 2002 and April
2009. Patients whose procedural coding included more
than one occurrence of the current procedural terminology
(CPT) codes 35474 (femoral or popliteal percutaneous
transluminal angioplasty [PTA]) or 37205/37206 (place-
ment of intravascular stent) were identified as patients who
potentially underwent repeat femoropopliteal endovascular
intervention. We completed a detailed review of these
patients’ charts and all angiograms of procedures to identify
occurrences of repeat angioplasty or stenting on a previ-
ously treated femoropopliteal segment. We defined this
as SPTAS. Indications, patient comorbidities, medication
usage, and time from the initial failed intervention and
SPTAS were obtained from chart abstraction. Anatomic
characteristics of both SPTAS and initial endovascular in-
terventions including TransAtlantic InterSociety Consen-
sus II (TASCII) classification, presence of a total occlusion,
presence of in-stent restenosis, and runoff score were de-
termined by detailed review of angiograms.
Endovascular technique and surveillance of endo-
vascular interventions. All interventions were performed
percutaneously by either vascular surgeons or interven-
tional cardiologists in the catheterization lab at Brigham
and Women’s Hospital. Techniques were at the discretion
of the operator but generally involved antegrade approach
via contralateral femoral access. Both .035 and .014 plat-
forms were utilized for angioplasty with or without stenting
depending on operator preference. Use of stents included
both selective stenting as indicated for residual stenosis or
flow-limiting dissection and primary stenting according to
operator discretion. Surveillance of revascularizations was
generally done with clinical examination, ankle-brachial
indices (ABIs), and duplex ultrasonography at 1, 3 to 6,
and 12 months, followed by testing yearly or as required.
Outcomes. Patency rates were determined from the
time of SPTAS, which was the index procedure in this
study. Primary patency and secondary patency rates were aefined in accordance with the suggested reporting stan-
ards of the Society for Vascular Surgery/International
ociety for Cardiovascular Surgery Ad Hoc Committee.8
ll revascularizations were evaluated via objective criteria
ncluding duplex ultrasonography or contrast arteriogra-
hy in 62 (88.6%) and maintenance of an ABI in eight
11.44%). Failure of patency was defined by either the need
or endovascular reintervention to maintain patency or a
rop in ABI .1 since the highest postintervention index.8
riteria for reintervention were recurrent symptoms in
onjunction with 75% stenosis (3:1 velocity increase in
ur laboratory) of a previously treated segment accessed via
uplex or angiogram. Early failure of the initial endovascu-
ar intervention was defined as need for SPTAS within 180
ays of the initial endovascular intervention. Limb salvage
as defined as freedom from transtibial or above-knee
mputation.
Statistical analysis. Descriptive statistics were used to
nalyze comorbidities, anatomic, and procedural character-
stics. Continuous variables were compared using the Stu-
ent t-test and categorical variables were compared using a
2 test or Fisher’s exact test where numbers in each group
ere small. Ordinal variables were compared between
roups using a Mantel-Haensel 2 trend test. Primary and
econdary patency, limb salvage, and patient survival rates
ere analyzed with Kaplan-Meier curves and the log-rank
est. Univariate and multivariable analysis of patient demo-
raphics and comorbidities, anatomic variables, and proce-
ural factors associated with outcomes were performed
ith a Cox proportional hazards model. Variables associ-
ted with outcome on univariate analysis (P .2) were
ncluded in the multivariable regression model to identify
actors independently associated with outcome. An  value
f .05, corresponding to P  .05 and 95% confidence
ntervals (CIs), was used as a criterion for statistical signif-
cance. Statistical computations were performed with SAS
9.1 (Cary, NC).
ESULTS
Demographics, indications, and comorbidities.
rom January 1, 2002 to April 1, 2009, 70 SPTAS were
erformed in 59 patients. The indication at SPTAS was
laudication in 54 (77%) and critical limb ischemia (CLI) in
6 (23%). Claudication was the indication for initial endo-
ascular intervention in 59 (84%) limbs. Patients were
rimarily Caucasian with a high prevalence of associated
omorbidities (Table I). The median (interquartile range)
ime between the initial endovascular intervention and
PTAS was 330 (range, 196-582) days. Sixteen SPTAS
23%) were performed after early failure of the initial endo-
ascular intervention, which was defined as SPTAS within
80 days of the initial intervention. There were no differ-
nces in comorbidities or indications between SPTAS per-
ormed after early failure of the initial procedure and those
hat were not.
Anatomic characteristics of lesions. TASC II classifi-
ation, the presence of total occlusions, in-stent restenosis,
nd new lesions in the femoropopliteal segment at SPTAS
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Volume 53, Number 3 Robinson et al 653are outlined in Table II. There were no differences in
anatomic severity of lesions at SPTASwith regards to TASC
level, presence of total occlusion, and run-off score be-
tween those undergoing SPTAS within 6 months or after 6
months from the initial endovascular failure.
Anatomic characteristics of lesions at the time of the
initial endovascular intervention are outlined in Table III.
There were no significant differences in TASC II classifica-
tion, percentage of total occlusions, and number of runoff
vessels at initial intervention as compared with SPTAS. In
addition, there were no significant differences in anatomic
characteristics of initial endoluminal interventions that
failed within 6 months and those that failed after 6 months
(data not shown). Stenting was performed in 41 limbs
(59%), while PTA without stenting was performed in 29
(41%) at the initial intervention. Fifty initial interventions
(71%) involved simultaneous iliac or tibial intervention.
Plavix was utilized in 66 (96%) of interventions.
The causes of failure of the initial endovascular inter-
Table I. Demographics, comorbidites, and indications
n (%)
Age 70.1  9.5 (50-90)
Male 37 (62.7%)
Race (Caucasian) 55 (94.8%)
Diabetes 19 (32.2%)
HTN 54 (91.5%)
Hyperlipidemia 54 (91.5%)
CAD 36 (61%)
CHF 9 (15.3%)
Smoker 16 (27.1%)
CRI 4 (6.8%)
Dialysis 0 (0)
CR 1.1  .47 (0-3.2)
Indication
Claudication 54 (77.1%)
Rest pain 10 (14.3%)
Ulcer 4 (5.7%)
Gangrene 2 (2.9%)
CAD, Coronary artery disease; CHF, congestive heart failure; CR, creati-
nine; CRI, chronic renal insufficiency; HTN, hypertension.
Table II. Anatomic characteristics of femoropopliteal
lesions treated at second-time femoropopliteal
percutaneous transluminal angioplasty/stenting (SPTAS)
n (%)
TASC II classification
A 18 (25.7%)
B 18 (25.7%)
C 25 (35.7%)
D 9 (12.9%)
Total occlusion 23 (32.9%)
In-stent restenosis 41 (58.6%)
Restenosis at PTA site 17 (24%)
New lesion 12 (17.14%)
PTA, Percutaneous transluminal angioplasty; TASC II, TransAtlantic Inter-
Society Consensus II.vention were in-stent restenosis in 41 (59%), restenosis wfter previous PTA alone in 17 (24%), and progression of
isease with new lesions in 12 patients (17%). Among those
xperiencing early failure of the initial endovascular inter-
ention, eight patients (50%) had failure after PTA alone,
even patients (44%) experienced in-stent restenosis, and
ne (6%) patient was characterized as having a new lesion
ot previously treated in the femoropopliteal segment. The
ode of failure of the initial endovascular intervention was
ot significantly different among those experiencing failure
efore 6 months and after 6 months.
Procedural characteristics of SPTAS. Forty-two
PTAS (60%) included angioplasty without stenting while
ntravascular stenting was performed in 28 procedures
40%). Adjunctive therapy was utilized to supplement an-
ioplasty stenting in 32 procedures (45.7%) and included
otational and laser atherectomy, cryoplasty, and brachy-
herapy. Twenty-two procedures (31%) involved treatment
f the femoropopliteal segment only, while 47 procedures
67%) involved concomitant treatment of either an iliac or
ibial lesion. In one procedure, lesions in each of the three
evels were treated. Concomitant lesions treated as well as the
umber of runoff vessels in continuity to the level of the ankle
t completion of SPTAS are outlined in Table IV.
Early results. SPTAS was performed with excellent
echnical success and a low rate of periprocedural compli-
ations (Table V). Sixty-one (87%) of patients reported
linical improvement at the first postoperative visit, and the
verage increase in ABI at 1 month was .25  .31. SPTAS
erformed after early failure of initial endovascular therapy
as associated with lower rate of reported improvement at
he first postprocedure visit (69% vs 93%; P  .02) and
ncreased intraprocedural complications (25% vs 6%; P 
044) although there was no difference in rate of technical
uccess in comparison to those without early failure (100%
s 96%; PNS). Use of heparin or warfarin in (25% vs 11%;
 NS) or clopidogrel (88% vs 98%; P  NS) was not
ifferent following SPTAS performed after early failure of
nitial endovascular therapy as compared with SPTAS with-
ut early failure.
Outcomes of SPTAS. Overall, 2-year primary patency
able III. Anatomic and procedural characteristics of
he initial endovascular intervention
n (%)
ASC II classification
A 13 (20.3%)
B 14 (21.9%)
C 29 (45.3%)
D 8 (12.5%)
otal occlusion 24 (37.5%)
unoff vessels
0 1 (1.6%)
1 10 (15.9%)
2 32 (50.8%)
3 20 (31.8%)
tent placement 41 (58.6%)
ASC II, TransAtlantic InterSociety Consensus II.as 33.2% (Fig 1). Over the course of follow-up, there were
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March 2011654 Robinson et al39 failures of primary patency of SPTAS. Of these 39, 31
patients underwent further revascularization. Twenty-
seven patients underwent endovascular reintervention (the
third endovascular intervention in the femoropopliteal seg-
ment) after failed SPTAS. Secondary patency of SPTAS was
63% (Fig 2). Four patients underwent surgical bypass, and
eight had no reintervention.
Eight failures of SPTAS occurred in 16 patients who
underwent SPTAS for CLI, resulting in a primary patency
of 50%. There were no amputations performed in patients
with patent SPTAS. Of those who failed, six underwent
additional revascularization. A third endovascular femoro-
popliteal intervention was performed in four limbs. Two
patients underwent femoral-distal bypass grafting. One pa-
tient progressed to below-knee amputation 3 months after
surgical bypass. One patient was judged not to have a
surgical bypass option and underwent amputation after
failed SPTAS. In those undergoing SPTAS for CLI, 2-year
Table IV. Procedural characteristics of second-time
femoropopliteal percutaneous transluminal angioplasty/
stenting (SPTAS)
n (%)
Levels treated
Femoropopliteal only 22 (31.4%)
Femoropopliteal and iliac or tibial 47 (67.1%)
Femoropopliteal, iliac, and tibial 1 (1.4%)
Iliac intervention 38 (54.3%)
Tibial intervention 11 (15.7%)
Stent placement 28 (40%)
Adjunctive therapy 32 (45.7%)
Runoff vessels
1 15 (21.7%)
2 33 (47.8%)
3 21 (30.4%)
Table V. Early results of second-time femoropopliteal
percutaneous transluminal angioplasty/stenting (SPTAS)
n (%)
Technical success 68 (97.1%)
Procedure complication
Access 1 (1.4%)
Embolism 1 (1.4%)
Dissection 5 (7.1%)
Postprocedure complication
MI/stroke 0/0
ARF 1 (1.4%)
Bleeding 2 (2.86%)
Discharge Plavix 67 (95.7%)
Discharge anticoagulation 10 (14.3%)
Discharge statin 58 (82.9%)
Improved at first visit 61 (87.1%)
Worse at first visit 2 (2.9%)
Change in ABI .25  .31 (.63-1.22)
Median LOS 1 day
ABI, Ankle-brachial index;ARF, acute renal failure; LOS, length of stay;MI,
myocardial infarction.limb salvage was 86.5%. The remaining 31 failures of bPTAS occurred in patients undergoing SPTAS for claudi-
ation. Of these failures, 25 limbs underwent additional
evascularization. A third endovascular intervention was
erformed in 23 limbs. Twelve remained patient for a
econdary patency of SPTAS of 53%. Two patients under-
ent surgical bypass. There were no amputations in pa-
ients undergoing SPTAS for claudication. Overall 2- and
-year survival were 88.5% and 83%, respectively.
Univariate analysis including demographics, comor-
ig 1. Primary patency of second-time femoropopliteal percuta-
eous transluminal angioplasty/stenting (SPTAS). The number at
isk and associated standard error (SE) at yearly time intervals are
hown in the table below each curve.
ig 2. Secondary patency of second-time femoropopliteal percu-
aneous transluminal angioplasty/stenting (SPTAS). The number
t risk and associated standard error (SE) at yearly time intervals are
hown in the table below each curve.idities, and timing of SPTAS, anatomic and procedural
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Volume 53, Number 3 Robinson et al 655characteristics of both SPTAS and the initial endovascular
intervention was performed to identify factors associated
with failure of patency of SPTAS. Only the use of clopi-
dogrel after SPTAS (hazard ratio [HR], .28; 95% CI,
.083-.95) and SPTAS within 6 months of initial endovas-
cular intervention (HR, 2.7; 95% CI, 1.4-5.2) showed
significant effect on failed primary patency of SPTAS. On
multivariable analysis, only early failure (180 days) of the
initial endovascular intervention was a significant predictor
of failed primary patency of SPTAS (2-year primary pa-
tency: SPTAS within 6 months of initial procedure, 7.8 
7.4%, vs SPTAS more than 6 months from initial proce-
dure, 43  8.7%; HR, 2.7; 95% CI, 1.4-5.2; Fig 3).
Likewise, on both univariate and multivariate analysis, early
failure (180 days) of the initial endovascular intervention
emerged as the only factor with a significant association
with failed secondary patency (2-year secondary patency:
SPTAS within 6 months of initial procedure, 60 9.6%, vs
SPTAS more than 6 months from initial procedure, 71%
7.7%; HR, 3.1; 95% CI, 1.4-7.1; Fig 4).
DISCUSSION
This study provides a novel characterization of the
results of SPTAS and the factors predictive of the outcome
of SPTAS in the femoropopliteal segment. Short-term
outcomes of SPTAS mirror that of primary endovascular
interventions. The technical success of SPTAS was 97%
with low periprocedural complications is comparable to
that reported for first-time endovascular interventions
for femoropopliteal occlusive disease.5,7,9 Short-term
efficacy is further evidenced by a median LOS of 1-day
Fig 3. Impact of early endovascular failure on primary patency of
second-time femoropopliteal percutaneous transluminal angio-
plasty/stenting (SPTAS). Primary patency of SPTAS of those with
early failure of the initial endovascular intervention (dashed line) vs
those without early failure of the initial endovascular intervention
(solid line), log-rank test; P  .0029. SE, Standard error.and reported clinical improvement by 87% of patients at eheir first postprocedure visit. The low morbidity and
arly of success of SPTAS likely reinforces the utilization
f repeat endoluminal revascularization for patients and
nterventionalists alike.
The midterm results, however, of SPTAS are not en-
ouraging and substantially inferior to those generally re-
orted for initial percutaneous transluminal angioplasty
ith or without stenting. Only 33.2% of SPTASmaintained
rimary patency at 2 years. With an additional endovascular
ntervention (a third overall intervention), a 2-year second-
ry patency SPTAS of 63% could be maintained. This is
imilar to the experience of Ryer et al who report 84%
econdary patency at 1 year and 40% secondary patency
fter 2 years in 46 patients who failed initial endovascular
ntervention.10 Treiman et al, in a study of 35 patients
reated for recurrent femoropopliteal stenosis between
983 and 1993, reported clinical and hemodynamic suc-
ess of 41% at 1 year, 20% at 2 years, and 11% at 3 years.11
espite limited durability, there is no evidence that poor
idterm patency portended limb loss, as limb salvage was
6.5% at 2 years in our limited sample of patients with CLI.
his is consistent with the 1-year limb salvage rate of 86%
eported by Ryer et al. However, the potential impact of
ailed repeat endovascular intervention on limb salvage in
atients with critical limb ischemia requires additional
tudy.
One might expect the determinants of outcome of
PTAS to mimic those of initial femoropopliteal angio-
lasty  stenting. Previous studies have identified a
ariety of factors that influence the success of initial
ig 4. Impact of early endovascular failure on secondary patency
f second-time femoropopliteal percutaneous transluminal angio-
lasty/stenting (SPTAS). Secondary patency of SPTAS of those
ith early failure of the initial endovascular intervention (dashed
ine) vs those without early failure of the initial endovascular
ntervention (solid line), log-rank test; P  .0049. SE, Standard
rror.ndovascular intervention: gender, diabetes, hyperten-
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March 2011656 Robinson et alsion, hyperlipidemia, critical limb ischemia, TASC clas-
sification, the need for multilevel intervention, distal
runoff status, and stenting.2-4,9,12-15
The demographics and comorbidities of patients in this
cohort were similar to those of previously published co-
horts undergoing first-time infrainguinal angioplasty. As
seen in reports from other centers with extensive endovas-
cular experience,9,12,14,16 the majority of our patients were
older males with multiple medical comorbidities. The indi-
cation for intervention was claudication in 77% of this
cohort, which is slightly higher than other series in which
55% to 70% of lower extremity interventions are under-
taken for claudication.9,12,14,16 This likely reflects a prefer-
ence for surgical bypass for those with critical limb ischemia
by operators at our institution. There was an extremely
high prevalence of Caucasians that reflects the demograph-
ics of our tertiary referral center.
The anatomic characteristics of lesions at the time of
the second endovascular interventions have not been well
characterized in the literature. Overall, lesions were of only
moderate severity according to TASC II classification.
Greater than 50% of SPTAS were performed on TASC A
and B lesions. This is consistent with results reported by
Joels et al, who found that 81% of 24 limbs requiring
reintervention for early failure of endovascular therapy in
the superficial femoral artery had TACS A and B dis-
ease.3,4,14,17 In addition, only one-third of lesions treated
at SPTAS were total occlusions, and 59% of lesions were
areas of in-stent restenosis, suggesting that these reinter-
ventions were often required for limited anatomic disease,
most often in previously treated areas. Patency of SPTAS in
this cohort was quite limited despite only moderate lesion
severity at SPTAS. In fact, lesion severity was not found to
predict outcome of SPTAS.
Anatomic severity of disease at the initial endovascular
intervention also did not predict outcome. The TASC II
classification and percentage of total occlusions at the pri-
mary endovascular intervention was not different than that
present at SPTAS. Only 12% of lesions were TASC D
lesions and 37.5% were total occlusions at initial therapy.
These results differ significantly from those of Ryer et al,
who reviewed the characteristics of initial failed angioplasty
in 46 patients and found that 64% of initial failures had
TADC D lesions.10 Because less severe anatomic severity
has been shown to be a positive prognostics factor in
first-time endovascular intervention, TASC II recom-
mendations extended the range of severity of lesions that
were recommended to be treated via percutaneous ther-
apy.3,4,11,18 However, our results suggest that there are
factors other than anatomic severity of disease that influ-
ence the response to endovascular therapy that have yet
to be elucidated.
The procedural characteristics of SPTAS have not been
well described previously. The majority of patients under-
going SPTAS required multilevel interventions, with con-
comitant iliac or tibial intervention performed in 69% of
cases. By comparison, in series of initial endovascular ther-
apy, 45% to 60% of procedures have been reported to cnvolve multilevel intervention.5,14 Fifty-nine percent of
rocedures involved treatment of in-stent restenosis. This is
onsistent with reports which indicate that stenting is per-
ormed in 45% to 65% of initial femoral and popliteal
ercutaneous interventions.9,14 Stents were also utilized at
PTAS in 40% of interventions. In addition, SPTAS in this
eries involved adjunctive procedures such as laser debulk-
ng, atherectomy, cryoplasty, and brachytherapy, in 45% of
ases. However, neither multilevel intervention, stenting,
or use of adjunctive procedures proved to have an impact
n the outcome of SPTAS.
In our multivariate analysis, early failure of the initial
ndovascular intervention proved to be the only significant
redictor of the outcome of SPTAS.17 Early failure of the
rimary endovascular intervention portended dismal pa-
ency of SPTASwith 7.8% 7.4% primary patency and 60%
9.6% secondary patency at 2 years. Our results differ
ignificantly with the results of Joels et al, who reported a
9% 1-year patency in 14 patients who underwent repeat
ndovascular intervention after early endovascular failure,
hich they defined as failure within 200 days from the time
f endovascular intervention.17 We chose a priori to define
early failure” as failure within 180 days because this pro-
ided a consistent definition of “early failure” in comparing
his endovascular experience with our previously reviewed
xperience with revision of failed infrainguinal bypass. We
reviously discovered that failure of lower extremity bypass
ithin 6 months of initial intervention predicted failure of
pen revision.19 The median time to failure of the initial
ndovascular intervention observed in this cohort (330
ays) is consistent with observations from other series. Ryer
t al and Derubertis et al reported the mean time to failure
f endovascular therapy to be 8.7 months and 8.5 months,
espectively.14,18
Interestingly, the results of this study mimic those in
urgical revision of failed infrainguinal bypass grafting as
eported by Nguyen et al in our group.19 Infrainguinal
ypass grafts that required revision within 6 months of
nitial bypass were more likely to require subsequent revi-
ion to maintain patency. The reasons for the detrimental
mpact of early endovascular failure are not clear. Early
ailure may represent factors that have not been charac-
erized to this point but which predispose endovascular
ntervention in that limb to failure. Further investigation
s clearly warranted into the pathophysiology of early
ailure.
We acknowledge the limitations of this study. There is
relatively small sample size, which might render the study
nderpowered to detect the impact of certain risk factors.
n addition, this is a patient population who was selected
or a continued endovascular approach and, therefore, may
ossess risk factors not known or measured in this study.
inally, this study design does not allow direct comparisons
o a group of patients who underwent surgical or medical
herapy after initial endovascular failure, and clinicians must
ontinue to tailor therapy to individual patients.
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SPTAS can be achieved with excellent technical success
and low morbidity. However, these data suggest that
SPTAS is not effective in establishing durable patency after
initial failure of endovascular therapy, as midterm patency is
limited and further reintervention is often required. In
particular, failure within 180 days of the initial endovascular
intervention portends very poor outcomes with SPTAS and
thus identifies a group of patients in whom a continued
endovascular approach is fruitless. Further studies are re-
quired to understand the pathophysiology of failure of
endovascular therapy and to identify those patients at high risk
for early failure. In addition, the clinical outcomes and cost-
effectiveness of surgical therapy vs continued endovascular
therapy in patients who fail an initial endovascular ap-
proach require further analysis.
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